Samuel R. Kaufman
YOU?
Author Swipe
View article: Employment of Independently Billing Advanced Practice Clinicians
Employment of Independently Billing Advanced Practice Clinicians Open
This cross-sectional study uses Medicare Data on Provider Practice and Specialty files from 2008 to 2021 to evaluate changes in rates of employment of advanced practice clinicians.
View article: A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer
A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer Open
Importance Among men with favorable-risk (ie, low-risk or favorable intermediate-risk) prostate cancer, confirmatory testing substantially improves the detection of aggressive cancers that may merit treatment instead of conservative manage…
View article: Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist
Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist Open
Introduction In the past decade, the management of advanced prostate cancer has shifted to novel hormonal therapies. As a result, urologists have increased their involvement in the management of advanced prostate cancer. These therapies re…
View article: Anticipated Out‐Of‐Pocket Costs and Prostate Cancer Management Among Men With Commercial Insurance
Anticipated Out‐Of‐Pocket Costs and Prostate Cancer Management Among Men With Commercial Insurance Open
Introduction Men with newly diagnosed prostate cancer often appropriately elect for either immediate treatment or conservative management. The out‐of‐pocket costs they face vary by management strategy, with immediate treatment often supers…
View article: Racial Differences in Care Quality Among Men With Newly Diagnosed Prostate Cancer
Racial Differences in Care Quality Among Men With Newly Diagnosed Prostate Cancer Open
This cross-sectional study examines racial disparities in care quality, including confirmatory testing and potential overtreatment, among Medicare beneficiaries with newly diagnosed prostate cancer.
View article: Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer
Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer Open
Introduction Medicare Advantage (MA) managed care plans, now chosen by 51% of Medicare beneficiaries, are incentivized to constrain healthcare spending and utilization, a shift in financial incentives compared to Traditional Medicare's fee…
View article: Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer
Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer Open
Importance Active surveillance in men with less aggressive prostate cancer is inconsistently used despite clinical guidelines. Renumeration generally favors treatment over conservative management and may contribute to the variable adoption…
View article: The <scp>340B</scp> Drug Pricing Program and Management of Advanced Prostate Cancer
The <span>340B</span> Drug Pricing Program and Management of Advanced Prostate Cancer Open
Introduction Oral targeted therapies are a standard of care for men with advanced prostate cancer. However, these therapies are expensive, which may be a barrier to some, particularly the most economically disadvantaged. Through investment…
View article: Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery
Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery Open
Introduction and Objectives Prior work has demonstrated racial disparities in surgical outcomes for solid organ cancers. We sought to assess the relationship between hospital quality and racial disparities in achievement of textbook outcom…
View article: Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare
Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare Open
Background For men with prostate cancer, there is substantial variation in the use of conservative management, such as active surveillance. Commercial prices, which vary across urology practices, may afford incentives that foster physician…
View article: The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer
The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer Open
In men with advanced prostate cancer, high-risk prescribing and futility measures did not vary by participation in the 340B drug pricing program.
View article: Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors
Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors Open
Background The use of androgen biosynthesis and second-generation androgen receptor inhibitors for advanced prostate cancer is increasing. Because these therapies alter the androgen pathway, they have been associated with cardiometabolic a…
View article: Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer
Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer Open
Background Urologists practicing in single‐specialty groups with ownership in radiation vaults are more likely to treat men with prostate cancer. The effect of divestment of vault ownership on treatment patterns is unclear. Methods A 20% s…
View article: Value‐based payment models and management of newly diagnosed prostate cancer
Value‐based payment models and management of newly diagnosed prostate cancer Open
Objective To examine the effect of urologist participation in value‐based payment models on the initial management of men with newly diagnosed prostate cancer. Methods Medicare beneficiaries with prostate cancer diagnosed between 2017 and …
View article: The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer
The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer Open
Introduction Some worry that physician practices acquired by private equity may increase the use of services to maximize revenue. We assessed the effects of private equity acquisition on spending, use of treatment, and diagnostic testing i…
View article: Acquisition of Urology Practices by Private Equity Firms and Performance in the Merit-based Incentive Payment System
Acquisition of Urology Practices by Private Equity Firms and Performance in the Merit-based Incentive Payment System Open
Private equity acquisition of urology practices was associated with significantly lower MIPS performance. As private equity acquisition of urology practices becomes more prevalent, key stakeholders should ensure that the quality of patient…
View article: Association Between Urologist Merit-Based Incentive Payment System Performance and Quality of Prostate Cancer Care
Association Between Urologist Merit-Based Incentive Payment System Performance and Quality of Prostate Cancer Care Open
Better performance in MIPS is associated with a higher rate of confirmatory testing in men initiating active surveillance for prostate cancer. However, performance was not associated with other dimensions of quality nor spending.
View article: In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer
In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer Open
Background Management of men with advanced prostate cancer has evolved to include urologists, made possible by oral targeted agents (eg, abiraterone or enzalutamide) that can be dispensed directly to patients in the office. We sought to in…
View article: Health care delivery system contributions to management of newly diagnosed prostate cancer
Health care delivery system contributions to management of newly diagnosed prostate cancer Open
Background Despite clinical guidelines advocating for use of conservative management in specific clinical scenarios for men with prostate cancer, there continues to be tremendous variation in its uptake. This variation may be amplified amo…
View article: Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer
Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer Open
In-office dispensing is increasingly common in urology practices. This emerging model is not associated with changes in patient volume but is associated with increased prescriptions for abiraterone and enzalutamide.
View article: Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities
Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities Open
PURPOSE: Black men have a higher risk of prostate cancer diagnosis and mortality but are less likely to receive definitive treatment. The impact of structural aspects on treatment is unknown but may lead to actionable insights to mitigate …
View article: Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer Open
Background Abiraterone and enzalutamide are the most common oral agents for the treatment of men with advanced prostate cancer. To understand their safety profiles in real-world settings, we examined the association between the use of abir…
View article: Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer Open
Urologists are increasingly prescribing oral targeted therapies to patients with advanced prostate cancer. Concurrent with this trend, urology practices are allowing patients to fill their prescription onsite or through a pharmacy establis…
View article: PD03-05 THE ROLE OF UROLOGY PRACTICE ORGANIZATION AND RACIAL COMPOSITION ON PROSTATE CANCER TREATMENT DISPARITIES
PD03-05 THE ROLE OF UROLOGY PRACTICE ORGANIZATION AND RACIAL COMPOSITION ON PROSTATE CANCER TREATMENT DISPARITIES Open
You have accessJournal of UrologyHealth Services Research: Practice Patterns, Quality of Life and Shared Decision Making I (PD03)1 Sep 2021PD03-05 THE ROLE OF UROLOGY PRACTICE ORGANIZATION AND RACIAL COMPOSITION ON PROSTATE CANCER TREATMEN…
View article: PD05-06 PROMOTIONAL PAYMENTS TO MEDICAL ONCOLOGISTS AND UROLOGISTS AND PRESCRIPTIONS FOR ABIRATERONE AND ENZALUTAMIDE
PD05-06 PROMOTIONAL PAYMENTS TO MEDICAL ONCOLOGISTS AND UROLOGISTS AND PRESCRIPTIONS FOR ABIRATERONE AND ENZALUTAMIDE Open
Increasing promotional payments were associated with prescribing among medical oncologists and urologists, with a stronger relationship evident for urologists. Prescribing patterns for abiraterone and enzalutamide, particularly among urolo…